无质粒型能够合成C3G的大肠杆菌及其构建方法和应用
By knocking out the β-glucosidase uidA gene in Escherichia coli BL21(DE3) and integrating C3G synthesis-related enzyme genes, a plasmid-free Escherichia coli was constructed using the CRISPR-Cas9 system. This solved the metabolic burden and glycosidic bond breakage problems caused by plasmids, and achieved efficient and stable C3G synthesis, which is suitable for industrial production.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- SHENYANG AGRI UNIV
- Filing Date
- 2026-06-03
- Publication Date
- 2026-07-17
AI Technical Summary
Existing E. coli C3G synthesis processes suffer from metabolic burdens and glycosidic bond breakage due to plasmid replication and proliferation, making them unsuitable for large-scale production. Furthermore, exogenous plasmid expression can easily lead to strain contamination.
By knocking out the β-glucosidase uidA gene in Escherichia coli BL21(DE3) and integrating the genes of C3G synthesis-related glycosyltransferase 3GT and anthocyanin synthase ANS at that site, a plasmid-free genome was constructed using the CRISPR-Cas9 gene editing system to achieve integrated genome expression.
This method enables efficient synthesis of C3G without antibiotics, reducing the metabolic burden caused by plasmids, improving biosafety and production stability, and making it suitable for industrial production.
Smart Images
Figure CN122405686A_ABST